The use of fluorouracil (5-FU) and leucovorin in women with heavily pretreated advanced ovarian carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 36, Issue 5, 2013, Pages 472-474

  Peled, Yoav ^a   Levavi, Hanoch ^a   Krissi, Haim ^a   Weill, Yehudah ^a   Sabah, Gad ^a   Eitan, Ram ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Advanced ovarian carcinoma; Chemotherapy; Fluorouracil

Indexed keywords

CA 125 ANTIGEN; FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; DEMOGRAPHY; DIARRHEA; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CARCINOMA; RETROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR RECURRENCE; VOMITING;

ADENOCARCINOMA, MUCINOUS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84885023545     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182549399     Document Type: Article

References (10)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(suppl 1): S161-S192.
3. Tummala MK, McGuire WP. Recurrent ovarian cancer. Clin Adv Hematol Oncol. 2005;3:723-736. (Pubitemid 41823989)
4. Oskay-Ozcelik G, Sehouli J. Pros and cons for systemic therapy in recurrent ovarian cancer. Anticancer Res. 2009;29:2831-2836.
5. Morgan RJ Jr, Speyer J, Doroshow JH, et al. Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels. Gynecol Oncol. 1995;58:79-85.
6. Look KY, Muss HB, Blessing JA, et al. A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study. Am J Clin Oncol. 1995;18:19-22.
7. Kamphuis JT, Huider MC, Ras GJ, et al. High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer. Cancer Chemother Pharmacol. 1995;37:190-192.
8. Long HJ III, Nelimark RA, Su JQ, et al. Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma. Gynecol Oncol. 1994;54:180-183. (Pubitemid 24256467)
9. Look KY, Blessing JA, Muss HB, et al. 5-fluorouracil and lowdose leucovorin in the treatment of recurrent epithelial ovarian carcinoma. A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol. 1992;15:494-496.
10. Reed E, Jacob J, Ozols RF, et al. 5-Fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma. Gynecol Oncol. 1992;46:326-329.